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As the disease caused by Mycobacterium tuberculosis continues to be a burden, there is a concerted effort
to find new vaccines to combat this problem. One of the important vaccine strategies is whole bacterial
vaccines. This approach relies on multiple antigens and built-in adjuvanticity. Other mycobacterial
strains which share cross-reactive antigens with M. tuberculosis have been considered as alternatives to M.
bovis for vaccine use. One such strain, “Mycobacterium w”, had been evaluated for its immunomodulatory
properties in leprosy. A vaccine against leprosy based on killed M. w is approved for human use, where it
has resulted in clinical improvement, accelerated bacterial clearance, and increased immune responses to
Mycobacterium leprae antigens. M. w shares antigens not only with M. leprae but also with M. tuberculosis,
and initial studies have shown that vaccination with killed M. w induces protection against tuberculosis
in Mycobacterium bovis BCG responder, as well as BCG nonresponder, strains of mice. Hence, we further
studied the protective potential of M. w and the underlying immune responses in the mouse model of
tuberculosis. We analyzed the protective efficacy of M. w immunization in both live and killed forms
through the parenteral route and by aerosol immunization, compared with that of BCG. Our findings
provide evidence that M. w has potential protective efficacy against M. tuberculosis. M. w activates
macrophage activity, as well as lymphocytes. M. w immunization by both the parenteral route and aerosol
adminstration gives higher protection than BCG given by the parenteral route in the mouse model of
tuberculosis.
The current vaccine against tuberculosis (TB), Mycobacte-
rium bovis BCG, fails to protect against the most prevalent
disease form, pulmonary TB in adults. It is generally assumed
that active TB occurs because of a weakening of the immune
system, which keeps Mycobacterium tuberculosis in check as
long as it is fully competent. M. tuberculosis does not induce the
optimum protection because the pathogen is not eradicated,
and it has now been shown that exogenous reinfection does
occur, suggesting that natural immunity is insufficient (26) and
fails to control the pathogen in the long run. Hence, other
mycobacterial strains which share cross-reactive antigens (Ags)
with M. tuberculosis have also been considered as alternatives
to M. bovis for vaccine use. One strain, “Mycobacterium w,”
had been evaluated for its immunomodulatory properties in
leprosy. M. w is a nonpathogenic, cultivable mycobacterium
(18) which has been found to improve immunity to leprosy
(30). A vaccine against leprosy based on M. w is approved for
human use, where it has resulted in clinical improvement,
accelerated bacterial clearance, and increased immune re-
sponses to Mycobacterium leprae Ags (13, 21, 25). M. w shares
Ags not only with M. leprae but also with M. tuberculosis (29),
and initial studies have shown that vaccination with killed M. w
induces protection against TB in animal models (22, 23) and
also resulted in early sputum conversion in TB patients (17).
Recently it has been suggested that M. w be referred to as
Mycobacterium indicus pranii to avoid confusion with M. tuber-
culosis-W (Beijing strain) (24). It is generally known that live
bacteria impart greater protection than killed bacteria. It may
be that persistence of live bacteria in the host for some time
results in a robust memory response (12). Another important
factor is that secretory proteins which are absent in the killed
bacterial vaccines have been shown to play an important role in
protection. In this study, we analyzed the M. tuberculosis-spe-
cific immune response induced in mice immunized with live or
killed M. w and compared it with the BCG-induced immune
response and also compared the protective efficacies of the two
mycobacteria.
As the lung is the primary target organ of this disease,
immunization potential by the aerogenic route was also stud-
ied. Inhalation of aerosols provides a noninvasive delivery sys-
tem that physically targets the lung as the desired site of the
pharmacological effect. This route of immunization has
emerged a very attractive route of vaccine delivery, inducing
both local and systemic immunity (7, 10). The immune re-
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sponse induced by live M. w given by aerosol was studied and
compared with those of other groups of immunized mice.
Establishment of a protective immune response during the
course of M. tuberculosis infection requires successful recruit-
ment of T lymphocytes and activation of macrophages. In our
present study, we demonstrate that immunization with M. w
activates macrophage activity, as well as lymphocytes, as indi-
cated by gamma interferon (IFN-) secretion and cytotoxic
activity toward infected macrophages. Activated macrophages
could inhibit the intracellular growth and multiplication of M.
tuberculosis. M. w immunization by both the parenteral route
and aerosol immunization gave higher protection than BCG
given by the parenteral route in the mouse model of TB.
MATERIALS AND METHODS
Animals. Inbred C57BL/6 mice at 6 weeks of age were obtained from the
animal facility of the National Institute of Immunology, New Delhi, India, where
animals are bred and housed in agreement with the guidelines of the Institute’s
Animal Ethics Committee.
Mycobacteria. M. w maintained on Lowenstein-Jensen medium (LJ) slants
(BD Difco) and kept at 70°C was grown in Middlebrook 7H9 medium (BD
Difco) with 0.02% glycerol, 0.05% Tween 80, and 10% albumin-dextrose com-
plex enrichment (BD Difco) as a shake flask culture. Bacteria were harvested in
the log growth phase by centrifugation at 840 g for 15 min, washed twice by the
centrifugal washing method, and suspended in saline at the desired concentra-
tion for immunization. Some of the bacteria were inactivated by autoclaving for
20 min at a pressure of 15 lb/in2.
Immunization. Five groups of C57BL/6 mice at 6 weeks of age were used. Two
groups were immunized with killed and live M. w bacteria, respectively, through
the subcutaneous (s.c.) route each at a dose of 107 bacteria in 100 l of saline
(preliminary experiments were done to find the optimum dose). The third group
was immunized with live M. w aerosol by an aerosol immunization device (3) as
described earlier. Respirable aerosol of the bacterial suspension was made by
passing compressed air through a nebulizer holding the bacterial suspension. The
concentration of the bacterial suspension in the nebulizer and the time of expo-
sure of mice to aerosol were standardized, which resulted in the deposition of
about 1,000 bacteria in one pair of lungs, as determined by CFU counting at 24 h
after immunization. The fourth group was immunized with 107 BCG (Danish
1331 strain) bacteria per mouse by the s.c. route. The fifth group was given a
saline injection by the s.c. route (control group). Three weeks after primary
immunization, a booster immunization was given with the same Ag and by the
same route as in the primary immunization. Three weeks after the booster
immunization, mice were sacrificed and different assays were performed.
Infection of mice. Mice were challenged with live M. tuberculosis H37Rv by the
aerosol route with an inhalation exposure system (Glas-Col, Terre Haute, IN).
About 300 to 400 M. tuberculosis bacilli per lung were delivered with the above
inhalation exposure system. The protective efficacy of vaccination in different
groups was evaluated by plating serial 10-fold dilutions of lung, spleen, and liver
homogenates in quadruplicate on LJ plates. Plates were incubated inside
semisealed plastic bags at 37°C for 3 to 4 weeks, and colonies were counted.
Bacterial loads in the lungs, spleens, and livers of different groups of immunized
and control mice were determined at 8 and 12 weeks after a challenge with M.
tuberculosis. Bacterial loads in four individual mice per group were determined
at each time point. Two mice were sacrificed for histopathological studies.
Lymphocyte proliferation assay. Spleens were aseptically removed and
crushed with sterile blunt forceps. A single-cell suspension was prepared, and red
blood cells were lysed with Gey’s solution. Cells were washed, and viability was
assessed by the trypan blue exclusion method after plating at a concentration of
4  105 per well in RPMI 1640 medium supplemented with 10% fetal calf serum
in a 96-well plate. These cells were stimulated in vitro with M. w Ag, M. tuber-
culosis Ag, or no Ag (control) in triplicate. After incubation for 72 h at 37°C and
5% CO2, cultures were pulsed with 1 Ci of [3H]thymidine. At 18 h later, cells
were harvested and [3H]thymidine uptake was measured with a beta counter.
The stimulation index was calculated by dividing the mean counts per minute of
Ag-stimulated cells by the mean counts per minute of corresponding unstimu-
lated cells.
Cytokine measurement. In the lymphocyte culture for proliferation, a dupli-
cate set was prepared for cytokine assay. Cell culture supernatant was collected
after 48 h of Ag stimulation and kept at 20°C until further use. The levels of
IFN- and interleukin-4 (IL-4) were measured with a mouse-specific enzyme-
linked immunosorbent assay kit (BD Pharmingen).
Bronchoalveolar lavage (BAL) to collect alveolar macrophages. Animals were
euthanized, and the thoracic cavity was exposed. The trachea was canulated with
a 26-gauge butterfly canula and secured with a silk thread. Lungs were lavaged
three times with a 1-ml aliquot of ice-cold saline to collect alveolar macrophages.
In vitro assessment of inhibition of mycobacterial growth in alveolar macro-
phages. Alveolar macrophages were harvested by centrifuging BAL fluid at
200  g for 5 min at 4°C. The pellet was suspended in 1 ml of complete medium
consisting of RPMI 1640 medium with 10% fetal calf serum and antibiotic
antimycotic solution. Cell counts were taken with a hemocytometer, and viability
was determined with trypan blue. Macrophages were taken from four mice per
group, and 5  104 macrophages per well were seeded in 500 l of complete
medium and allowed to adhere. Lymphocytes were prepared from spleen sam-
ples, and 5  105 lymphocytes per well were stimulated in vitro with 2 g of
soluble Ag of M. w for 48 h. Alveolar macrophages were infected with live M.
tuberculosis H37Ra at a 20:1 multiplicity of infection overnight. Infected macro-
phages were washed thrice with RPMI medium to remove the extracellular
bacteria after infection. Infected macrophages were then cocultured with stim-
ulated lymphocytes for 72 h, after which supernatants were aspirated and mac-
rophages were lysed with 0.2% saponin for 2 min to release the intracellular
bacteria. Viable bacteria present in the lysate were determined by plating dif-
ferent dilutions of the lysate on 7H11 agar plates supplemented with 10% oleic
acid-albumin-dextrose-catalase (BD Difco).
Frequency of IFN--producing cells. To evaluate the lung response further, M.
tuberculosis Ag-specific IFN--secreting lymphocytes were quantitated by en-
zyme-linked immunospot (ELISPOT) assay. Briefly, macrophages were collected
from BAL fluid as described earlier. Lungs were taken from four mice in each
group and cut into small pieces. These were suspended in RPMI medium and
treated with collagenase type IA-S (Sigma) for 30 min at 37°C and homogenized
briefly with a homogenizer, and the resulting cell suspension was passed through
a sterile nylon wool column to get a single-cell suspension of lymphocytes. We
plated 3  104 macrophages and 3  105 lymphocytes per well of 96-well
nitrocellulose-backed plates along with M. tuberculosis Ag and incubated the
plates for 48 h. The plates were processed by following the instructions given with
the kit, and the spots in the air-dried plates were counted in an ELISPOT reader
with KS Elispot software.
FIG. 1. IFN- secretion by lymphocytes from different groups of
immunized mice on restimulation with M. w Ag or M. tuberculosis
(M.tb) Ag in vitro. Sonicate supernatant of M. w or M. tuberculosis at
a concentration of 2 g per well was used as the Ag for in vitro
restimulation. Data are expressed as the mean SEM (n 4 mice per
group). ***, P  0.001.
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Cell-mediated cytotoxicity assay. The CD8 T-cell-mediated cytotoxicity of
different groups of immunized mice toward infected and uninfected syngeneic
macrophages collected from BAL fluid was studied by flow cytometry. This
method is considered a promising alternative to the use of radioactive isotopes
for these analyses (9). Briefly, CD8 T cells were isolated from lymphocytes with
CD8a antibody conjugated with magnetic nanoparticles (BD Biosciences, Phar-
mingen). Target cells were labeled with the fluorescent cell membrane marker
PKH-67 (Sigma). Effector (CD8 T cells) and target (M. tuberculosis-infected or
uninfected macrophages) cells were cocultured at a 2:1 ratio for 8 h in a six-well
tissue culture plate. The nuclear marker 7-aminoactinomycin D (Molecular
Probes; Invitrogen) was added to distinguish between live and dead cells. Sam-
ples were run in a flow cytometer (BD LSR). A minimum of 10,000 events were
collected and analyzed with WinMDI software.
Statistical analysis. Results are shown as the mean the standard error of the
mean (SEM). Comparisons between groups were performed by analysis of vari-
ance. P values of 0.05 were considered statistically significant.
RESULTS
Immune response to M. w. As IFN- is a crucial component
of antimycobacterial immunity, the induction of this cytokine
by in vitro restimulation of lymphocytes was assessed. It was
observed that M. w aerosol immunization induced significantly
higher IFN- compared to immunization by the s.c. route. Live
M. w by the s.c. route, in turn, induced a significantly higher
IFN- response compared to killed M. w (Fig. 1). IL-4 secre-
tion was also checked. None of the immunized groups showed
a detectable amount of IL-4 (data not shown).
Cell-mediated cytotoxicity. It has been shown convincingly
that CD8 T cells have a role in protection against M. tuber-
culosis. Hence, cell-mediated cytotoxicity of CD8 T cells iso-
lated from different groups of immunized mice were studied in
Ag-pulsed and unpulsed syngeneic macrophages from BAL
fluid. The percentage of dead target cells was significantly
higher in M. w aerosol-immunized mice compared to the group
of mice immunized by the s.c. route with live or killed M. w
(Fig. 2). The cell-mediated cytotoxicity of M. w in the aerosol
group and the live M. w s.c. group was significantly higher than
that in BCG-immunized mice and control mice. These results
provide evidence that M. w immunization also activates a
CD8 T-cell response.
Intracellular growth inhibition activity of macrophages.
Multiple mechanisms are important for inhibition of intracel-
lular mycobacteria. To further study the lung-specific immune
response, the intracellular growth inhibition activity of alveolar
macrophages was studied. There was an about 80% reduction
in the number of viable bacteria in alveolar macrophages col-
lected from the M. w aerosol-immunized group compared to
the control group (Fig. 3). The percent reduction in this group
was significantly higher than in the other three groups. An
about 55% reduction in intracellular bacteria was observed in
the live M. w s.c. group, which was higher than in the BCG
group (P 0.05), where an about 38% reduction was observed.
Cocultures of alveolar macrophages and lymphocytes were
analyzed for nitric oxide and reactive oxygen, as these are
implicated in the killing of intracellular bacteria. It was ob-
served that after 72 h of coculture, reactive oxygen and nitric
oxide levels were significantly higher in the M. w aerosol-
immunized group than in the control group (data not shown).
Local lung immune response. BAL fluid collected from M. w
aerosol-immunized mice, as well as control mice, was analyzed
for secretory immunoglobulin A (IgA) antibody. A significantly
FIG. 2. Cell-mediated cytotoxicity of CD8 T cells isolated from
different groups of immunized or unimmunized mice toward M. tuber-
culosis Ag-pulsed syngeneic macrophages from BAL fluid. Target cells
were labeled with PKH-67. The nuclear marker 7-aminoactinomycin D
was added to distinguish between live and dead cells. Cells were taken
from four mice per group for this study. The results shown here are
representative of two similar experiments. *, P  0.05; ***, P  0.001.
FIG. 3. Intracellular growth inhibition activity of alveolar macro-
phages. Macrophages collected from the BAL fluid of all groups of
immunized or control mice were infected in vitro with M. tuberculosis
H37Ra and cocultured with lymphocytes for 72 h. The number of
viable bacilli present inside macrophages after 72 h were determined
by CFU counting. Cells were taken from four mice per group for this
study. The results shown here are representative of two similar exper-
iments. ***, P  0.001.
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higher IgA antibody response was induced in aerosol-immu-
nized mice than in those parenterally injected with M. w and in
control mice (Fig. 4A). These studies indicate that immuniza-
tion with M. w aerosol results in the activation of a local lung
immune response.
The cytokines IL-12 and IFN-, as markers of activation of
macrophages and lymphocytes, were quantitated in BAL fluid
by enzyme-linked immunosorbent assay. Moderate amounts of
both cytokines were present in the BAL fluid supernatant of
M. w aerosol-immunized mice, but these were significantly
higher than those in control mice (Fig. 4B and C).
Kinetics of immune response. The kinetics of the immune
responses in the lungs, spleens, and lymph nodes of all five
groups of mice were studied at different time points after
booster immunization by the s.c. or aerosol route.
Ag-specific IFN--secreting cells in the lungs were quanti-
tated by ELISPOT, as lymphocyte proliferation of lung cells
was low (data not shown). We have checked the response in
the lungs until 4 weeks after a booster immunization. Signifi-
cantly higher numbers of IFN--secreting cells could be seen in
the lungs of all of the groups of mice immunized with M. w
than in control mice at 1 week after a booster immunization
(Fig. 5). The number of IFN--secreting cells decreased grad-
ually in all of the groups until 4 weeks, but in M. w aerosol-
immunized mice, the number was higher at all time points than
in the other groups.
Ag-specific lymphocyte proliferation and IFN- secretion in
the supernatant were quantified at different time points for
lymphocytes collected from the spleen and lymph nodes. We
separated the brachial lymph nodes of mice immunized by the
aerosol route and the inguinal lymph nodes of those immu-
nized by the s.c. route. We found that the Ag-specific prolif-
FIG. 4. (A) Secreted IgA antibody in BAL fluid supernatant. (B and C) Cytokines IL-12 and IFN-, respectively, in BAL fluid supernatant. ***,
P  0.001.
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erative response in the spleen peaked at 2 to 3 weeks after
the booster immunization while the immune response in the
lymph nodes peaked at 3 to 4 weeks after immunization
(Fig. 6). Until 10 weeks, a specific immune response was
observed, although quantitatively it decreased gradually
from 4 weeks onward. When we evaluated the IFN- secre-
tion in the supernatant of in vitro-restimulated lymphocytes
from the spleen, it was observed that until 6 weeks there was
a very high level of IFN- secretion in the M. w aerosol
group (Fig. 7). Then again at 10 weeks there was an increase
in IFN- secretion both in the M. w aerosol group and in the
live M. w s.c. group. This is an interesting observation, which
could be related to the persistence of live M. w in mice for
about 6 to 7 weeks, during which activated effector T cells
which secrete IFN- are generated. But once the live bac-
teria are cleared, there is a surge of memory T cells which
produce IFN-. (The persistence of live M. w in mice was
checked by plating organ homogenates on LJ plates at dif-
ferent time points after immunization [data not shown].)
Further analysis and experiments are necessary to define the
phenotype of T cells secreting IFN- at different time
points. These studies provide evidence that M. w immuni-
zation of mice leads to activation of T cells and macro-
phages in lymphoid organs.
Protection against M. tuberculosis challenge. The bacterial
loads in different organs were determined. It was observed
that 8 weeks after challenge, M. w aerosol immunization
reduced the lung bacterial load about eight times compared
to the control while M. w immunization by the s.c. route
reduced the bacterial load about five times (data not
shown). The reduction in the bacterial load produced by M.
w immunization was significantly greater than that in the
BCG-immunized group and the control group. The splenic
load was about 50 to 100 times less than the lung bacterial
load in all of the groups.
At 12 weeks postinfection, the lung bacterial load was 12
times less in the M. w aerosol-immunized group than in the
control group and was also significantly less than in all of the
other immunized groups (Fig. 8). The second best protection
was given by the live M. w s.c. group, which was higher than
that of the killed M. w s.c. group in all of the organs studied.
One important observation was that in the M. w aerosol-im-
munized group, the bacterial load in the lungs decreased from
8 to 12 weeks while in the rest of the groups, there was some
increase in the number of bacteria in the lungs, although it was
not significant. At 12 weeks postinfection, in both the live M. w
aerosol and s.c. groups, the bacterial loads in the liver and
spleen were similar. In the liver, there was an about eight times
reduction in both of the groups while in spleen there was a four
to five times reduction in both of the groups compared to the
FIG. 5. IFN--secreting lymphocytes from the lungs of all groups
of immunized or control mice on in vitro restimulation with M.
tuberculosis Ag as determined by ELISPOT assay. Lymphocytes
taken from four mice per group at each time point were used for
this assay. Data are expressed as the mean  SEM.
FIG. 6. Kinetics of immune responses in the spleen and lymph nodes. M. tuberculosis Ag-specific lymphocyte proliferation at different time
points is shown. Data are expressed as the mean SEM (n 4 mice per group at each time point). The stimulation index is the counts per minute
of Ag-stimulated cells divided by the counts per minute of unstimulated cells.
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control. This observation suggests that the systemic protection
given by two different routes of immunization is similar while
the protection afforded by aerosol immunization in the lung is
greater.
Mice were checked for body weight at different time inter-
vals after infection, as it correlates with the extent of disease.
In the control group of mice, there was an about 15 to 20%
weight loss at 8 weeks after infection (data not shown). But
interestingly, there was a 5 to 8% gain in weight in M. w
aerosol-immunized mice at this time, which reflects protection
in M. w-immunized mice.
Histopathological observation. In keeping with significant
immune protection in M. w-immunized mice, there was
much reduced lung histopathology in these mice compared
to that in control, unimmunized mice. After a challenge with
M. tuberculosis H37Rv, unimmunized control mice devel-
oped a grossly evident number of nodular lung lesions and
hemorrhagic spots, which were quite large compared to
those of M. w-immunized mice (data not shown). When
sections from immunized and unimmunized groups of mice
were compared at 8 and 12 weeks postchallenge with M.
tuberculosis, it was found that the number and size of gran-
ulomas in the M. w-immunized mice were smaller and they
were surrounded by healthy alveolar architecture. These
granulomas consisted primarily of tight aggregates of lym-
phocytes and were more organized in immunized mice and
there was less parenchymal inflammation and slower pro-
gression of lung pathology than in control unimmunized
mice, where diffused granulomas were seen and areas of
nongranulomatous infiltrating portions were quite evident
(Fig. 9). Distended alveolar spaces (edematic lung) were
also seen in unimmunized mice, suggesting a relative loss of
lung function. This was not seen in M. w-immunized mice.
Large numbers of extracellular and intracellular bacilli were
seen in sections of lungs of control mice, compared to very
rare extracellular bacilli in M. w-immunized mice (Fig. 10).
DISCUSSION
TB can occur at any tissue site, but the lung is the primary
target organ of this disease. Inhaled bacteria are engulfed by
alveolar macrophages. Macrophages are the effector cells,
while T lymphocytes are the specific mediators of resistance to
TB. IFN- produced by T cells activates antimycobacterial
activities in macrophages and has been shown to be crucial for
protection against TB (14, 15). Although it is not perfect, at
present IFN- is considered the most attractive correlate of
protective immunity. Hence, we started our study by evaluating
the lymphocyte proliferation- and IFN- secretion-inducing
capacities of M. w.
In order to accelerate the control of initial M. tuberculosis
infection, vaccine-induced immunity in the lung must be
further enhanced. It has been shown that M. tuberculosis is
considerably more virulent when administrated by the re-
spiratory route compared to the intravenous route, largely
because of the delayed expression of immunity in the lung
(4, 5). In this study, we have observed that M. w induces a
Th1 type of response whether given in killed or live form.
Aerosol immunization with M. w induced the greatest T-cell
response compared to all of the other groups studied, espe-
cially the local lung response. Increasing evidence suggests
that vaccination at the mucosal site is superior to vaccina-
tion at other sites in eliciting protection from mucosal in-
fectious diseases (16). This is partially explained by the
observation that memory T and B cells generated upon
mucosal vaccination acquire mucosa-homing receptors and
preferentially accumulate at the mucosal site of induction
(4, 5). However, few mucosally delivered TB vaccines, ex-
cept replicating mycobacteria, could successfully trigger
protective immune responses in the lung (7, 10). Vaccina-
tion of humans by the nasal route could also offer practical
advantages for vaccine administration, as this is a noninva-
sive delivery system.
In our study, aerosol immunization induced both an Ag-
FIG. 7. Kinetics of immune responses in the spleen and lymph nodes. IFN- secreted in the supernatant of in vitro restimulated lymphocytes
is shown. Data are expressed as the mean  SEM (n  4 mice per group at each time point).
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specific IgA response and local and systemic T-cell immune
responses. Secretory IgA antibody has been shown to play a
major role in host protection against bacterial and viral patho-
gens by blocking pathogen entrance and/or by modulating the
proinflammatory responses (19, 27).
To achieve significant protection, it is necessary to induce
different components of the immune response. CD8 T cells
are required to achieve significant protection against TB (11,
20). Hence, the cell-mediated cytotoxicity of CD8 T cells was
studied. This assay potentially measures one of the most rele-
vant biological parameters. Our findings indicate that besides
IFN-, M. w also induces significant CD8 T-cell cytotoxic ac-
tivity.
Mycobacterial survival and replication depend on a com-
plicated interplay between various host and mycobacterial
factors. Most studies of mycobacterial immunity have fo-
cused on T-cell proliferation, cytokine production, and cy-
tolytic activity, but the effects of these in vitro responses on
the intracellular viability and growth of mycobacteria are
also crucial (28). Cytolytic assays demonstrate specific lysis
of infected monocytes by immune cells, but intracellular
growth inhibition is not demonstrated by these assays. The
mechanisms responsible for growth inhibition could be the
activation of macrophage effector functions, viz., production
of toxic effector molecules like reactive nitrogen and reac-
tive oxygen (6), limiting the availability of iron to mycobac-
teria, or apoptosis. Paradoxically, macrophages are also the
main host cells of M. tuberculosis (15). Results of intracel-
lular growth inhibition activity of alveolar macrophages
from M. w-immunized mice provide evidence that macro-
phage effector functions are activated by M. w immuniza-
tion. This assay provides a more direct measure of in vivo
resistance to M. tuberculosis. The panel of assays done in this
study provides information about different aspects of myco-
bacterial immunity.
It has been proposed that persistent Ags which provide
FIG. 8. Bacterial loads in the lungs (A), spleens (B), and livers (C) of different groups of immunized and control mice at 12 weeks after
challenge with M. tuberculosis H37Rv. Bacterial loads in four individual mice per group were determined, and the results of one of two similar
experiments are shown. *, P  0.05; **, P  0.01; ***, P  0.001.
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strong T-cell stimuli over extended periods of time activate
effector T cells efficiently but exhaust memory (1, 2). What
is required is a vaccine that can persist long enough to
generate memory T cells but still gradually gets cleared by
the host immune response without generating adverse pa-
thology (8). It is probable that the immune response in-
duced by a viable vaccine which persists for only a restricted
time period best fulfills these requirements. In this study,
the presence of M. w in the lungs of immunized mice was
checked at different time points after immunization. At 6 to
7 weeks after immunization, no viable bacteria were de-
tected, as determined by CFU counting on LJ plates (data
not shown). This provides evidence that infection with M. w
is self-limiting and short-lived, which is important for the
induction of a memory response and also from a safety point
of view.
In summary, our findings provide evidence that M. w has
potential protective efficacy against M. tuberculosis. The
lung bacterial load was lowest in the M. w aerosol-immu-
nized group, while the liver and splenic loads were similar
after immunization by both routes. These results support
the notion that the immune system is sort of compartmen-
talized and responses are often strongest in compartments
proximal to the site of vaccine application. M. w activates
macrophage activity, as well as lymphocytes, as indicated by
IFN- secretion and cytotoxic activity toward infected mac-
rophages. Activated macrophages could inhibit the intracel-
lular growth and multiplication of M. tuberculosis. M. w
immunization by both the parenteral and aerosol routes
gives higher protection than BCG given by the s.c. route in
the mouse model of TB. Our current findings warrant fur-
ther evaluation with guinea pigs and other large animals,
FIG. 9. Hematoxylin-eosin-stained sections of M. tuberculosis-infected lungs of control mice (A, B, and C) and M. w-immunized mice (D, E,
and F) at 12 weeks postinfection. The arrows in panels A and B indicate lymphocyte infiltration and aggregates of lymphocytes. An extensive
inflammatory reaction and infiltration were seen in the sections. Frequent edema formation was also seen in the lungs of control mice (C). In
contrast to those of controls, sections of M. w-immunized mice had localized areas of infiltration surrounded by healthy alveolar structure (D and
E). Small, organized granulomas were seen, and there was less parenchymal inflammation (F).
FIG. 10. Lung sections of control mice (A) and M. w-immunized mice (B) stained with carbolfuchsin and counterstained with hematoxylin.
Large numbers of extracellular and intracellular bacilli were seen in the sections of control mice, compared to very rare extracellular and few
intracellular bacilli in M. w-immunized mice.
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along with comparison of long-term protection potential in
different immunized groups.
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